Loading...
•
Dec 31, 2024
Evolus Q4 2024 Earnings Report
Evolus reported record Q4 2024 revenue with continued strong growth.
Key Takeaways
Evolus achieved a record fourth-quarter revenue of $79.0 million, representing a 30% increase year-over-year. The company reported a GAAP operating loss of $2.3 million, with a positive non-GAAP operating income of $6.7 million. Cash and cash equivalents increased to $87.0 million, reflecting strong sales growth and prudent expense management.
Q4 2024 revenue grew 30% year-over-year to $79.0 million.
Non-GAAP operating income reached $6.7 million, showing profitability improvements.
Cash and cash equivalents increased to $87.0 million.
Continued expansion of Jeuveau and launch preparations for Evolysse in 2025.
Evolus
Evolus
Forward Guidance
Evolus expects strong revenue growth in 2025, with new product launches contributing to expansion.
Positive Outlook
- 2025 revenue guidance of $345M to $355M, a 30-33% increase.
- Evolysse and Estyme products expected to contribute 8-10% of revenue.
- Company expects to achieve positive non-GAAP operating income in 2025.
- Continued expansion of Jeuveau in the U.S. and internationally.
- Projected total revenue of at least $700M by 2028 with 20% operating margin.
Challenges Ahead
- Investments in Evolysse launch may weigh on short-term profitability.
- Non-GAAP operating income concentration expected in Q4 2025.
- Market adoption of new products remains uncertain.
- Competition in the aesthetic medicine space continues to increase.
- Regulatory and reimbursement challenges could impact financial results.